# Progesterone vs Clobetasol Propionate in Vulvar Lichen Sclerosus

> **NCT01126255** · PHASE2 · TERMINATED · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 37 (actual)

## Conditions studied

- Vulvar Lichen Sclerosus

## Interventions

- **DRUG:** Clobetasol propionate 0.05%
- **DRUG:** Progesterone 8%

## Key facts

- **NCT ID:** NCT01126255
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-03
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 37 (ACTUAL)
- **Why stopped:** Recruitment problems
- **Last updated:** 2022-04-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01126255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01126255, "Progesterone vs Clobetasol Propionate in Vulvar Lichen Sclerosus". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01126255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*